Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia
- 12 August 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 136 (7), 909-913
- https://doi.org/10.1182/blood.2019004352
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMMLBlood, 2017
- Kahl BS, Yang DT. Follicular lymphoma: evolving therapeutic strategies. Blood. 2016;127(17):2055-2063.Blood, 2016
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agentsNature Communications, 2016
- Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthmaBMJ Open, 2016
- The genomic landscape of juvenile myelomonocytic leukemiaNature Genetics, 2015
- An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adultsBlood, 2015
- ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patientsLeukemia, 2014
- GM-CSF–dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemiaBlood, 2013
- Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced STAT5 activation and target-gene expression during human monocyte/macrophage differentiationJournal of Leukocyte Biology, 2002